Abstract
Immune checkpoint inhibitors induce durable responses in some patients with advanced cancer but may simultaneously trigger autoinflammatory immune-related adverse events (irAE). The pathogenesis of irAEs may relate to genetic predisposition, environmental insults, or tumor–host interactions. Elevated expression of certain cytokines may signal subclinical inflammation that evolves into severe irAEs with treatment.
See related article by Lim et al.
- Received November 27, 2018.
- Revision received December 6, 2018.
- Accepted December 18, 2018.
- Published first December 26, 2018.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Published OnlineFirst January 17, 2019
doi: 10.1158/1078-0432.CCR-18-3858
